This study is testing a drug called panitumumab-IRDye800 to see how well it helps doctors find head and neck cancer during surgery. The drug works as a monoclonal antibody, which means it's designed to target specific cells. Researchers want to see if panitumumab-IRDye800 can make cancer cells glow, making them easier to see compared to healthy tissue. They will also be looking at the safety of this drug. You may be able to join if you are an adult with squamous cell carcinoma (a type of cancer) of the head and neck that requires surgery. The study aims to enroll 25 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 25 participants.

What's involved

Participants will receive a single dose infusion of panitumumab-IRDye800CW. Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will measure the tumor to background ratio of fluorescence from Day 0 through Day 15 after receiving the drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.